Literature DB >> 2542116

Hepatocellular carcinoma without cirrhosis in Japanese patients.

K Okuda1, T Nakashima, M Kojiro, Y Kondo, K Wada.   

Abstract

Hepatocellular carcinoma is closely associated with cirrhosis, but it also develops, although much less frequently, in a noncirrhotic liver. It is suspected, without supporting evidence, that hepatocellular carcinoma has a different etiology when associated and not associated with chronic liver disease. In this study, 66 noncirrhotic cases found among 618 autopsies for hepatocellular carcinoma (10.7%) were analyzed retrospectively. The noncirrhotic liver was histologically unremarkable in 3 cases and in the histologically evaluable 56 cases it had fibrosis of varying degrees or mild cellular infiltrate, or both, in the portal tract. There was one liver that had portal venous changes compatible with those in idiopathic portal hypertension (Banti's syndrome). In these noncirrhotic livers, the parenchymal cells were generally unremarkable except for liver cell dysplasia that was seen in 26.8%. Serum hepatitis B surface antigen was positive in only 7.4% in contrast to 26.6% in cirrhotic cases. Three histologically unremarkable cases had no clinical or histologic evidence of chronic liver disease; two involved painter-plasterers and one a farmer. The liver weight in these cases ranged from 4400 to 6180 g. In contrast, the average liver weight in cirrhotic cases was 1998 g. Noncirrhotic patients when compared with cirrhotic patients had better liver function tests and much less frequent varices. It was concluded that approximately 11% of hepatocellular carcinoma cases in Japan are noncirrhotic, the majority having some histologic changes in the portal tracts suggestive of past or ongoing chronic liver disease, and that there are rare cases that have no histologic changes in the liver.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542116     DOI: 10.1016/0016-5085(89)91427-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Giant metastatic liver in a patient with small-cell neuroendocrine carcinoma of the lung.

Authors:  J Briese; D Hatton; F Stellmacher; H-P Horny
Journal:  Virchows Arch       Date:  2003-12-12       Impact factor: 4.064

Review 2.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension.

Authors:  Yumiko Isobe; Takahiro Yamasaki; Yuichirou Yokoyama; Fumie Kurokawa; Keisuke Hino; Isao Sakaida
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

Review 4.  Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma.

Authors:  A Lonardo; P Tarugi; G Ballarini; A Bagni
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

5.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

Review 6.  Geographic heterogeneity of hepatocellular carcinoma.

Authors:  K Okuda
Journal:  Gastroenterol Jpn       Date:  1990-12

7.  Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.

Authors:  Petr Pancoska; Sheng-Nan Lu; Brian I Carr
Journal:  J Gastrointest Dig Syst       Date:  2013-03-02

8.  Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis.

Authors:  Ivan Chebib; Meer Taher Shabani-Rad; Michelle S Chow; James Zhang; Zu-Hua Gao
Journal:  Biomark Insights       Date:  2007-02-14

9.  Thrombocytosis and hepatocellular carcinoma.

Authors:  Brian I Carr; Vito Guerra
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

10.  Dramatic down-regulation of oxidoreductases in human hepatocellular carcinoma hepG2 cells: proteomics and gene ontology unveiling new frontiers in cancer enzymology.

Authors:  Lambert C M Ngoka
Journal:  Proteome Sci       Date:  2008-10-24       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.